Pharma BD Deal Intelligence
Lilly pads cancer drug pipeline with Scorpion deal gaining once-daily oral PI3K-alpha inhibitor that could address 30-40 percent of HR-positive breast cancer.
"This is an example of a target that we've been working on ourselves for years," said Daniel Skovronsky, the Lilly CSO, in an interview near the annual J.P.…
Phase 3, randomized, double-blind, placebo-controlled study of tersolisib (LY4064809/STX-478) + CDK4/6 inhibitor + endocrine therapy in treatment-naive…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Eli Lilly acquired Scorpion Therapeutics' mutant-selective PI3Kalpha inhibitor program (lead asset STX-478) for up to $2.5 billion - $1 billion upfront plus up to $1.5 billion in regulatory and sales milestones - announced at JPM25 on January 13, 2025 and closed March 14, 2025. Lilly retained only the PI3Kalpha program; Scorpion's remaining assets were spun out into Antares Therapeutics (launched June 2025 with $177M). Post-close, Lilly renamed STX-478 tersolisib (development code LY4064809). Updated Phase 1/2 PIKALO-1 data presented at ESMO 2025 (Annals of Oncology LBA26; 204 patients as of July 7, 2025) showed a 23% objective response rate with tersolisib monotherapy in PIK3CA-mutant breast cancer and a tolerability profile (hyperglycemia ~31%) favorable versus wild-type-active PI3Kalpha inhibitors, supporting the mutant-selective differentiation thesis. Lilly advanced the asset to Phase 3: PIKALO-2 (NCT07174336), a randomized placebo-controlled study of tersolisib plus a CDK4/6 inhibitor and endocrine therapy in first-line HR+/HER2- PIK3CA-mutant advanced breast cancer (n=920), began recruiting December 22, 2025, with primary completion estimated May 2029.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Scorpion Therapeutics (this deal) | 2025 | $2.5B | 64 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2025 deals · Eli Lilly and Company deals · Oncology deals